AstraZeneca Canada v. Mylan Pharmaceuticals

In a first-of-its-kind ruling, the Federal Court of Can-ada decided on Feb. 7 in favor of Mylan Pharmaceuticals ULC’s argument that the patent for a combination drug to treat arthritis pain marketed by AstraZeneca Canada Inc. should be invalid based on the theory of obviousness. Mylan’s win means that generic (and presumably cheaper) forms of the drug will soon be available to Canadian consumers.